## Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced\ 01/07/96\ Origin:\ Appendix\ 5\ Amended\ 01/07/98,\ 01/09/99,\ 01/07/00,\ 30/09/01,\ 11/03/02,\ 01/01/03,\ 24/10/05,\ 01/08/12,\ 04/03/13,\ 01/08/12,\$ 

|        | INTEGRATED I  | RESEARCH LIMITED   |
|--------|---|--|
| ABN    | 76 003 588 449  |  |
| We (th | ne entity) give ASX the following info  | ormation.  |
|        | 1 - All issues st complete the relevant sections (attach shee   | ts if there is not enough space).  |
| 1      | <sup>+</sup> Class of <sup>+</sup> securities issued or to be issued  | N/A  |
| 2      | Number of *securities issued or to be issued (if known) or maximum number which may be issued   | 89,800 ordinary shares   |
| 3      | Principal terms of the <sup>+</sup> securities (e.g. if options, exercise price and expiry date; if partly paid <sup>+</sup> securities, the amount outstanding and due dates for payment; if <sup>+</sup> convertible securities, the conversion price and dates for conversion) | Issued on the exercise of vested Performance Rights (IRIAY) granted under the terms of the Integrated Research Performance Rights and Option Plan. 89,800 issued at an average exercise price of \$0.00. |

Name of entity

<sup>+</sup> See chapter 19 for defined terms.

| 4  | Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?  | N/A  |
|----|--|--|
|    | If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment |  |
| 5  | Issue price or consideration   | N/A  |
| 6  | Purpose of the issue<br>(If issued as consideration for the<br>acquisition of assets, clearly identify<br>those assets)  | Issued on the exercise of vested Performance Rights granted under the terms of the Integrated Research Performance Rights and Option Plan. |
|    |  |  |
| 6a | Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?  | No   |
|    | If Yes, complete sections 6b – 6h <i>in relation to the</i> +securities the subject of this Appendix 3B, and comply with section 6i  |  |
| 6b | The date the security holder resolution under rule 7.1A was passed   | N/A  |
| 6с | Number of *securities issued without security holder approval under rule 7.1   | N/A  |
| 6d | Number of *securities issued with security holder approval under rule 7.1A   | N/A  |
| бе | Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)  | N/A  |

| 6f | Number of ${}^{+}$ securities issued under an exception in rule 7.2   | N/A                   |                        |
|----|---|-----------------------|------------------------|
| 6g | If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.                    | N/A                   |                        |
| 6h | If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements  | N/A                   |                        |
| 6i | Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements  | N/A                   |                        |
| 7  | <sup>+</sup> Issue dates  | 31 August 2018        |                        |
|    | Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. |                       |                        |
|    | Cross reference: item 33 of Appendix 3B.  |                       |                        |
| 8  | Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)   | Number<br>171,770,753 | +Class Ordinary Shares |

<sup>+</sup> See chapter 19 for defined terms.

| 9 | Number     | and +   | class of | all <sup>+</sup> securities | not |
|---|------------|---------|----------|-----------------------------|-----|
|   | quoted     | on      | ASX      | (including                  | the |
|   | +securitie | es in s | ection 2 | if applicable)              | )   |

| Number  | +Class                              |
|---|-------------------------------------|
| 90,000  | Employee Performance Rights - IRIAT |
| Note:   |                                     |
|   |                                     |
| 60,000  | Employee Performance Rights - IRIAW |
| <u>Note</u> :                                       |                                     |
|   |                                     |
| Nil   | Employee Performance Rights - IRIAY |
| Note:   |                                     |
| 89,800 IRIAY Employee Performance Rights previously |                                     |
| issued have vested.                                 |                                     |
| 1,100 IRIAY Employee                                |                                     |
| Performance Rights previously                       |                                     |
| granted have been cancelled.                        |                                     |
|   | 5 1 5 6 5 11 1914                   |
| 110,000   | Employee Performance Rights - IRIAA |
| Note:   |                                     |
| 400,000   | Employee Performance Rights - IRIAZ |
| 400,000   | Employee Performance Rights - IRIAZ |
| Note: 39.000 IRIAZ Employee                         |                                     |
| 39,000 IRIAZ Employee Performance Rights previously |                                     |
| issued have been cancelled                          |                                     |
| 210,000   | Employee Performance Rights - IRIAA |
| Note:   |                                     |
|   |                                     |

| 10 | Dividend po    | olicy (in | the | case | of a trust |
|----|----------------|-----------|-----|------|------------|
|    | distribution   | policy)   | on  | the  | increase   |
|    | capital (inter | rests)    |     |      |            |

| N/A |  |  |  |
|-----|--|--|--|
|     |  |  |  |
|     |  |  |  |

#### Part 2 - Pro rata issue

| 11 | Is security holder approval required?  |
|----|--|
|    |  |
| 12 | Is the issue renounceable or non-renounceable?                                       |
|    |  |
| 13 | Ratio in which the <sup>+</sup> securities will be offered                           |
|    |  |
| 14 | <sup>+</sup> Class of <sup>+</sup> securities to which the offer relates             |
|    |  |
| 15 | <sup>+</sup> Record date to determine entitlements                                   |
|    | <u> </u>   |
| 16 | Will holdings on different majetars (or  |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating |
|    | entitlements?  |
|    |  |
| 17 | Policy for deciding entitlements in relation to fractions                            |

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

| 18 | Names of countries in which the entity has security holders who will not be sent new offer documents  |  |
|----|---|--|
|    | Note: Security holders must be told how their entitlements are to be dealt with.  |  |
|    | Cross reference: rule 7.7.  |  |
| 19 | Closing date for receipt of acceptances or renunciations  |  |
| 20 | Names of any underwriters   |  |
| 21 | Amount of any underwriting fee or commission  |  |
| 22 | Names of any brokers to the issue   |  |
| 23 | Fee or commission payable to the broker to the issue  |  |
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders  |  |
| 25 | If the issue is contingent on security holders' approval, the date of the meeting   |  |
| 26 | Date entitlement and acceptance form and offer documents will be sent to persons entitled   |  |
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders |  |
| 28 | Date rights trading will begin (if applicable)  |  |
| 29 | Date rights trading will end (if applicable)  |  |
| 30 | How do security holders sell their entitlements <i>in full</i> through a broker?  |  |
| 31 | How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?   |  |

<sup>+</sup> See chapter 19 for defined terms.

| 32                | How do security holders dispose of their entitlements (except by sale through a broker)?   |              |
|-------------------|--|--------------|
| 33                | <sup>+</sup> Issue date  |              |
|                   | 3 - Quotation of securities ed only complete this section if you are applying for quotation of   | f securities |
| 34                | Type of *securities (tick one)   |              |
| (a)               | *Securities described in Part 1  |              |
| (b)               | All other +securities  Example: restricted securities at the end of the escrowed period incentive share securities when restriction ends, securities issued o          |              |
|                   | es that have ticked box 34(a) ional securities forming a new class of securities   |              |
| Tick to<br>docume | to indicate you are providing the information or<br>nents  |              |
| 35                | If the *securities are *equity securities, the additional *securities, and the number and per those holders  | =            |
| 36                | If the +securities are +equity securities, a +securities setting out the number of holders in 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over |              |
| 37                | A copy of any trust deed for the additional +sec   | curities     |

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

### Entities that have ticked box 34(b)

| 38 | Number of *securities for which *quotation is sought   |        |        |
|----|--|--------|--------|
|    |  |        |        |
| 39 | <sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought  |        |        |
|    |  |        |        |
| 40 | Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  |        |        |
|    | If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust,  |        |        |
|    | <ul> <li>distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>   |        |        |
| 41 | Daniel Carrier of Carr |        |        |
| 41 | Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period   |        |        |
|    | (if issued upon conversion of another *security, clearly identify that other *security)  |        |        |
|    |  |        |        |
|    |  | Number | +Class |
| 42 | Number and *class of all *securities quoted on ASX ( <i>including</i> the *securities in clause 38)  |        |        |
|    |  |        |        |

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 3<sup>rd</sup> September 2018 (Company Secretary)

Print name: David C Purdue

== == == == ==

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.